Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
주식 순위
#3510
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
주가
$3.86
시가총액
$4.88B
변동 (1일)
4.10%
변동 (1년)
-50.30%
국가
CN
거래 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
카테고리
Healthcare
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)의 매출
Jun 2026 기준 매출 TTM: $293.29M
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $293.29M입니다. 2023년에 회사는 $778.51M의 수익을 올렸으며 이는 2022년의 $1.62B 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.의 수익 기록 (2013 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $293.29M | -4.66% |
| 2024 | $307.63M | -60.49% |
| 2023 | $778.51M | -51.99% |
| 2022 | $1.62B | 79.23% |
| 2021 | $904.72M | 151.05% |
| 2020 | $360.38M | 111.99% |
| 2019 | $170.00M | 19.00% |
| 2018 | $142.86M | -2.11% |
| 2017 | $145.94M | 20.04% |
| 2016 | $121.57M | 15.98% |
| 2015 | $104.83M | 8.90% |
| 2014 | $96.26M | 17.00% |
| 2013 | $82.27M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 4,204.41% |
US
|
|
| $2.23B | 659.66% |
US
|
|
| $15.74B | 5,268.23% |
AU
|
|
| $6.02B | 1,953.03% |
NL
|
|
| - | - |
CH
|
